Ascelia Pharma’s Q2 confirms some COVID delays - Redeye

The lead project Orviglance (also called Mangoral, an improved contrast agent addressing liver metastases) is slightly delayed by up to 6m due to COVID (Delta) related effects on the patient flow. Oncoral (improved efficacy and tolerability for chemotherapy addressing metastatic gastric cancer) remain on track, and that Ascelia’s newly opened US Office supports the direct US sales strategy for the US launch in 2023.

Länk till analysen i sin helhet: https://www.redeye.se/research/818925/ascelia-pharmas-q2-confirms-some-covid-delays?utm_source=finwire&utm_medium=RSS